Portfolio news 0

Rebrand marks transition into clinical-stage development and expansion of preclinical programs into new inflammatory disease targets using SSO platform.

MELBOURNE, AUSTRALIA, 15 May 2026 — Atisama Therapeutics (formerly Rage Bio) (“Atisama” or the “Company”), an Australian clinical-stage biotechnology company developing precision splice-switching oligonucleotide (SSO) therapeutics for chronic inflammatory disease, today announced its rebrand from Rage Bio to Atisama Therapeutics.

Corporate Rebrand: Rage Bio to Atisama Therapeutics

The change from Rage Bio to Atisama Therapeutics marks the Company’s transition from a discovery-stage entity operating under a working name into a clinical-stage therapeutics company. The Company’s new corporate website (atisama.com) provides additional insights.

Atisama comes from Sanskrit roots of ‘superior’ and ‘balanced state’, a reference to the Company’s approach of restoring molecular balance disrupted in chronic inflammatory disease.

“Becoming Atisama Therapeutics is more than a change of name, it marks our transition into a clinical-stage company and reflects what our science is built to do. Our platform is designed to restore the molecular balance that inflammatory disease has disrupted.” said Dr Siro Perez, Chief Executive and Scientific Officer.

About Atisama Therapeutics

Atisama Therapeutics Pty Ltd (ACN 640 194 770, formerly Rage Bio Pty Ltd) is a clinical-stage biotechnology company developing novel splice-switching oligonucleotide (SSO) therapies for inflammatory disease. Founded on the principle of restoring molecular balance for lasting health, the Company’s SSO platform is producing drug candidates that down-regulate disease-driving isoforms and upregulates their protective counterparts; a dual-action mechanism unique to the SSO modality. Atisama’s lead asset, RB042, is an inhaled SSO currently in Phase 1 clinical development. Atisama has several other programmes leveraging the novel SSO platform. The Company is headquartered in Melbourne, Australia.

For more information, visit www.atisama.com or contact [email protected].